Anti-CD19 Therapeutics to Manage Patients with Anti-AQP4 Antibody Positive Neuromyelitis Optics Spectrum Disorder
Anti-CD19 Therapeutics to Manage Patients with Anti-AQP4 Antibody Positive Neuromyelitis Optics Spectrum Disorder is organized by AcademicCME.
Program Dates: March 23, 2023 - March 22, 2024
Program Overview:
This CME program, derived from content presented at the Pre-ACTRIMS Advanced Curriculum for Multiple Sclerosis 2023 CME Course in San Diego, California, will highlight the use of anti-CD19 therapeutics to manage patients with anti-AQP4 antibody positive neuromyelitis optica spectrum disorder (NMOSD). The expert faculty, Prof. Hans-Peter Hartung, will first analyze the methodologies for a timely and accurate diagnosis of NMOSD. Next, Prof. Hartung will review recent data for neuromyelitis optica (NMO) therapeutics. Following, he will assess most current and effective treatment plans to improve outcomes in patients with anti-AQP4 antibody positive NMOSD. Upon completion of this activity, learners will gain a better understanding of how to utilize anti-CD19 therapeutics to manage patients with anti-AQP4 antibody positive NMOSD.
Learning Objectives:
• Review the methodologies for a timely and accurate diagnosis of NMOSD
• Analyze recent data for NMO therapeutics, including anti-CD19 B cell depleters for patients with anti-AQP4 antibody positive NMOSD
• Become aware of the most current and effective treatment plans to improve outcomes in patients with anti-AQP4 antibody positive NMOSD
Additional details will be posted as soon as information is available.